Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes

Clinical and Vaccine Immunology

Volumn 14, Issue 2, 2007, Pages 182-189

  Holman, David H ^a   Wang, Danher ^a   Raviprakash, Kanakatte ^c,d   Raja, Nicholas U ^a   Luo, Min ^a   Zhang, Jianghui ^a   Porter, Kevin R ^c,d   Dong, John Y ^a,b  

^a GenPhar Inc   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c NAVAL MEDICAL RESEARCH CENTER   (United States)

^d Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; DENGUE VACCINE; NEUTRALIZING ANTIBODY; VIRUS VACCINE; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CLINICAL FEATURE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENGUE; DENGUE VIRUS; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROTYPE; VACCINATION; VIRUS STRAIN;

ADENOVIRIDAE; ANIMALS; CELL LINE; CERCOPITHECUS AETHIOPS; DENGUE; DENGUE VACCINES; DENGUE VIRUS; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED C57BL; SEROTYPING; VERO CELLS;

EID: 33947103559     PISSN: 15566811     EISSN: None     Source Type: Journal    
DOI: 10.1128/CVI.00330-06     Document Type: Article

References (37)

1. Allison, S. L., K. Stadler, C. W. Mandl, C. Kunz, and F. X. Heinz. 1995. Synthesis and secretion of recombinant tick-borne encephalitis virus protein E in soluble and particulate form. J. Virol. 69:5816-5820.
2. Barouch, D. H., and G. J. Nabel. 2005. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum. Gene Ther. 16:149-156.
3. Blaney, J. E., Jr., J. M. Matro, B. R. Murphy, and S. S. Whitehead. 2005. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J. Virol. 79:5516-5528.
4. Bray, M., R. Men, and C. J. Lai. 1996. Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge. J. Virol. 70:4162-4166.
5. Chambers, T. J., Y. Liang, D. A. Droll, J. J. Schlesinger, A. D. Davidson, P. J. Wright, and X. Jiang. 2003. Yellow fever virus/dengue-2 virus and yellow fever virus/dengue-4 virus chimeras: biological characterization, immunogenicity, and protection against dengue encephalitis in the mouse model. J. Virol. 77:3655-3668.
6. Cohen, P. 2006. Immunity's yin and yang. A successful vaccine must first avoid being eliminated by pre-existing immunity before it can promote a protective immune response. IAVI Rep. 10:1-5.
7. Crill, W. D., and J. T. Roehrig. 2001. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J. Virol. 75:7769-7773.
8. Edelman, R., S. S. Wasserman, S. A. Bodison, R. J. Putnak, K. H. Eckels, D. Tang, N. Kanesa-Thasan, D. W. Vaughn, B. L. Innis, and W. Sun. 2003. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am. J. Trop. Med. Hyg. 69:48-60.
9. Gubler, D. J. 1998. Dengue and dengue hemorrhagic fever. Clin. Microbiol. Rev. 11:480-496.
10. Guirakhoo, F., S. Kitchener, D. Morrison, R. Forrat, K. McCarthy, R. Nichols, S. Yoksan, X. Duan, T. H. Ermak, N. Kanesa-Thasan, P. Bedford, J. Lang, M. J. Quentin-Millet, and T. P. Monath. 2006. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum. Vaccines 2:60-67.
11. Guirakhoo, F., R. Weltzin, T. J. Chambers, Z. X. Zhang, K. Soike, M. Ratterree, J. Arroyo, K. Georgakopoulos, J. Catalan, and T. P. Monath. 2000. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J. Virol. 74:5477-5485.
12. Henchal, E. A., M. K. Gentry, J. M. McCown, and W. E. Brandt. 1982. Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence. Am. J. Trop. Med. Hyg. 31:830-836.
13. Henchal, E. A., J. M. McCown, M. C. Seguin, M. K. Gentry, and W. E. Brandt. 1983. Rapid identification of dengue virus isolates by using monoclonal antibodies in an indirect immunofluorescence assay. Am. J. Trop. Med. Hyg. 32:164-169.
14. Henchal, E. A., and J. R. Putnak. 1990. The dengue viruses. Clin. Microbiol. Rev. 3:376-396.
15. Huang, C. Y., S. Butrapet, K. R. Tsuchiya, N. Bhamarapravati, D. J. Gubler, and R. M. Kinney. 2003. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J. Virol. 77:11436-11447.
16. Jaiswal, S., N. Khanna, and S. Swaminathan. 2003. Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type 2. J. Virol. 77:12907-12913.
17. Kitchener, S., M. Nissen, P. Nasveld, R. Forrat, S. Yoksan, J. Lang, and J. F. Saluzzo. 2006. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 24:1238-1241.
18. Kochel, T., S. J. Wu, K. Raviprakash, P. Hobart, S. Hoffman, K. Porter, and C. Hayes. 1997. Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice. Vaccine 15:547-552.
19. Konishi, E., S. Kosugi, and J. I. Imoto. 2006. Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. Vaccine 24:2200-2207.
20. Konishi, E., and P. W. Mason. 1993. Proper maturation of the Japanese encephalitis virus envelope glycoprotein requires cosynthesis with the pre-membrane protein. J. Virol. 67:1672-1675.
21. Konishi, E., M. Yamaoka, I. Kurane, and P. W. Mason. 2000. A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice. Vaccine 18:1133-1139.
22. - cytotoxic T-cell clones. J. Virol. 68:3283-3288.
23. McBride, W. J., and H. Bielefeldt-Ohmann. 2000. Dengue viral infections: pathogenesis and epidemiology. Microbes Infect. 2:1041-1050.
24. National Institute of Allergy and Infectious Diseases, National Institutes of Health. 2005. Dengue fever fact sheet. National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD. http: //www.niaid.nih.gov/factsheets/dengue.htm.
25. Nwanegbo, E., E. Vardas, W. Gao, H. Whittle, H. Sun, D. Rowe, P. D. Robbins, and A. Gambotto. 2004. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin. Diagn. Lab. Immunol. 11:351-357.
26. Ocazionez Jimenez, R., and B. A. Lopes da Fonseca. 2000. Recombinant plasmid expressing a truncated dengue-2 virus E protein without co-expression of prM protein induces partial protection in mice. Vaccine 19:648-654.
27. Raviprakash, K., T. J. Kochel, D. Ewing, M. Simmons, I. Phillips, C. G. Hayes, and K. R. Porter. 2000. Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein. Vaccine 18:2426-2434.
28. Raviprakash, K., K. R. Porter, T. J. Kochel, D. Ewing, M. Simmons, I. Phillips, G. S. Murphy, W. R. Weiss, and C. G. Hayes. 2000. Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques. J. Gen. Virol. 81:1659-1667.
29. Rubinchik, S., J. Woraratanadharm, J. Schepp, and J. Y. Dong. 2003. Improving the transcriptional regulation of genes delivered by adenovirus vectors. Methods Mol. Med. 76:167-199.
30. Sullivan, N. J., T. W. Geisbert, J. B. Geisbert, L. Xu, Z. Y. Yang, M. Roederer, R. A. Koup, P. B. Jahrling, and G. J. Nabel. 2003. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424:681-684.
31. Sullivan, N. J., A. Sanchez, P. E. Rollin, Z. Y. Yang, and G. J. Nabel. 2000. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408:605-609.
32. Sun, W., R. Edelman, N. Kanesa-Thasan, K. H. Eckels, J. R. Putnak, A. D. King, H. S. Houng, D. Tang, J. M. Scherer, C. H. Hoke, Jr., and B. L. Innis. 2003. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am. J. Trop. Med. Hyg. 69(Suppl. 6):24-31.
33. Timofeev, A. V., S. V. Ozherelkov, A. V. Pronin, A. V. Deeva, G. G. Karganova, L. B. Elbert, and J. R. Stephenson. 1998. Immunological basis for protection in a murine model of tick-borne encephalitis by a recombinant adenovirus carrying the gene encoding the NS1 non-structural protein. J. Gen. Virol. 79:689-695.
34. Van Kampen, K. R., Z. Shi, P. Gao, J. Zhang, K. W. Foster, D. T. Chen, D. Marks, C. A. Elmets, and D. C. Tang. 2005. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 23:1029-1036.
35. Wang, D., M. Hevey, L. Y. Juompan, C. M. Trubey, N. U. Raja, S. B. Deitz, J. Woraratanadharm, M. Luo, H. Yu, B. M. Swain, K. M. Moore, and J. Y. Dong. 2006. Complex adenovirus-vectored vaccine protects guinea pigs from three strains of Marburg virus challenges. Virology 353:324-332.
36. Wang, D., N. U. Raja, C. M. Trubey, L. Y. Juompan, M. Luo, J. Woraratanadharm, S. B. Deitz, H. Yu, B. M. Swain, K. M. Moore, W. D. Pratt, M. K. Hart, and J. Y. Dong. 2006. Development of a cAdVax-based bivalent Ebola vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus. J. Virol. 80:2738-2746.
37. Wang, D., A. L. Schmaljohn, N. U. Raja, C. M. Trubey, L. Y. Juompan, M. Luo, S. B. Deitz, H. Yu, J. Woraratanadharm, D. H. Holman, K. M. Moore, B. M. Swain, M. K. Hart, W. D. Pratt, and J. Y. Dong. 2006. De novo syntheses of Marburg virus antigens from adenovirus vectors induce potent humoral and cellular immune responses. Vaccine 24:2975-2985.